The Strategic Action in Health (AES) of the Carlos III Health Institute (ISCIII) is the main funding programme for biomedical and health research in Spain. Through its annual competitive calls, the ISCIII helps to promote both high-quality biomedical research projects from different centres in the country and the professional careers of the research community.
In this sense, the Bellvitge Biomedical Research Institute (IDIBELL) has been able to benefit once again from the resources offered by the ISCIII. With the 2024 call IDIBELL has received, on the one hand, 1.8 million euros for human resources for the staff contract and, on the other hand, a total amount of 3.8 million euros, with an expected duration of 3 years and concluding at the end of 2027, to 14 research projects of the centre. The lines of research that will benefit are those led by the following researchers:
Cancer Area
- Laia Alemany Vilches (ICO-IDIBELL)
- Jordi Bruna Escuer, CoIP: Roser Velasco Fargas (HUB-IDIBELL)
- Amparo García Tejedor (HUB-IDIBELL)
- David Llobet Navàs (IDIBELL)
- Ernest Nadal Alforja (ICO-IDIBELL)
- Josep Maria Piulats Rodríguez (ICO-IDIBELL)
- Miguel Ángel Pujana Genestar, CoIP: Francesca Mateo González (ICO-IDIBELL)
- Marta Simó Parra (HUB-IDIBELL)
Area of Translational Medicine
- Juliana Bordignon Draibe, Co-IP: Joan Torras Ambros (HUB-IDIBELL)
- Jordi Camara Mas (HUB-IDIBELL)
- Alberto Garay Melero (IDIBELL)
- Carlota Gudiol González (HUB-IDIBELL)
Regenerative Medicine Area
- Jordi Guiu Sagarra (IDIBELL)
In addition, within the Area of Translational Medicine, three more grants have been awarded not directly linked to research projects. Dr. María Molina Molina (HUB-IDIBELL) has received a grant for the improvement of the Clinical Research Unit for cutting-edge therapies, and Drs. José María Cruzado Garrit (HUB-IDIBELL) and Manuel Jesús Gómez Choco (CSI-IDIBELL) have been awarded the grant linked to the call for Cooperative Research Networks Oriented to Health Results (RICORS) for RICORS-Renal and RICORS-Ictus, respectively.
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).